(Source: Active Biotech AB) Tasquinimod Phase II retrospective follow-up study shows an impact of tasquinimod on bone metastases as measured by Bone Scan Index (BSI) Lund (Sweden), June 3, 2013. Active Biotech (NASDAQ OMX NORDIC: ACTI) today presented Phase II retrospective follow-up data from the prostate cancer project with tasquinimod at the scientific conference "2013 ASCO Annual Meeting" held in Chicago (USA). This study was performed in collaboration with EXINI Diagnostics AB (publ). Today Dr. Andrew J. Armstrong from the Duke Cancer Institute (Durham, NC) presented "Tasquinimod and effects on bone scan index in men with metastatic castration-resistant prostate cancer...
↧